Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02474355




Registration number
NCT02474355
Ethics application status
Date submitted
27/05/2015
Date registered
17/06/2015
Date last updated
11/11/2021

Titles & IDs
Public title
Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
Scientific title
Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy With an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)
Secondary ID [1] 0 0
D5160C00022
Universal Trial Number (UTN)
Trial acronym
ASTRIS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Surgery - T790M+ Testing
Treatment: Surgery - Baseline Visit Blood & Urine Testing
Treatment: Surgery - Baseline ECG
Treatment: Surgery - Visual Slit-Lamp Testing
Treatment: Drugs - AZD9291 Dosing

Experimental: AZD9291 - Single arm of AZD9291, starting dose of 80mg


Treatment: Surgery: T790M+ Testing
If a previous lab report is unavailable, the patient will need to have T790M+ testing.

Treatment: Surgery: Baseline Visit Blood & Urine Testing
Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria

Treatment: Surgery: Baseline ECG
ECG to ensure absence of any cardiac abnormality

Treatment: Surgery: Visual Slit-Lamp Testing
Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms

Treatment: Drugs: AZD9291 Dosing
Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
Intervention code [1] 0 0
Treatment: Surgery
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
From the date of first dose of Osimertinib until the date of death (due to any cause) or last participant contact [up to 43 months]
Primary outcome [2] 0 0
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [2] 0 0
From screening to progression follow-up [every 6 weeks +/- 1 week] relative to the date of enrolment until the end of study [up to 43 months]
Secondary outcome [1] 0 0
Progression Free Survival
Timepoint [1] 0 0
From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]
Secondary outcome [2] 0 0
Time to Treatment Discontinuation (TTD)
Timepoint [2] 0 0
From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]
Secondary outcome [3] 0 0
Response Rate (RR)
Timepoint [3] 0 0
From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]

Eligibility
Key inclusion criteria
1. Provision of signed and dated written informed consent by the patient or legally acceptable representative prior to any study-specific procedures
2. Adults (according to each country regulations for age of majority)
3. Locally advanced (stage IIIB) or metastatic (stage IV) EGFRm NSCLC, not amenable to curative surgery or radiotherapy, with confirmation of the presence of the T790M mutation
4. Prior therapy with an EGFR-TKI. Patients may have also received additional lines of treatment
5. World Health Organization (WHO) performance status 0-2
6. Adequate bone marrow reserve and organ function as demonstrated by complete blood count, biochemistry in blood and urine at baseline (please refer to IB for guidance)
7. ECG recording at baseline showing absence of any cardiac abnormality as per exclusion criterion #6
8. Female patients of childbearing potential must be using adequate contraceptive measures, must not be breast feeding, and must have a negative pregnancy test prior to start of dosing. Otherwise, they must have evidence of nonchildbearing potential
9. Male patients must be willing to use barrier contraception, i.e., condoms
Minimum age
18 Years
Maximum age
130 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Previous (within 6 months) or current treatment with AZD9291
2. Patients currently receiving (or unable to stop use at least 1 week prior to receiving the first dose of AZD9291) any treatment known to be potent inhibitors or inducers of cytochrome P450 (CYP) 3A4
3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, active infection including hepatitis B, hepatitis C, and human immunodeficiency virus, or significantly impaired bone marrow reserve or organ function, including hepatic and renal impairment, which in the investigator's opinion would significantly alter the risk/benefit balance.
4. Patient with symptomatic central nervous system (CNS) metastases who is neurologically unstable or has required increasing doses of steroids to manage CNS symptoms within the 2 weeks prior to start AZD9291 administration;
5. Past medical history of ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
6. Any of the following cardiac criteria:

1. Mean resting corrected QT interval (QTcF) > 470 ms using Fredericia's formula :
2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block)
3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
7. Any unresolved toxicity from prior therapy CTCAE > grade 3 at the time of starting treatment
8. History of hypersensitivity to excipients of AZD9291 or to drugs with a similar chemical structure or class to AZD9291

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/09/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/04/2019
Sample size
Target
Accrual to date
Final
3017
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Bedford Park
Recruitment hospital [2] 0 0
Research Site - East Melbourne
Recruitment hospital [3] 0 0
Research Site - Kurralta Park
Recruitment hospital [4] 0 0
Research Site - Randwick
Recruitment hospital [5] 0 0
Research Site - Waratah
Recruitment postcode(s) [1] 0 0
5042 - Bedford Park
Recruitment postcode(s) [2] 0 0
3002 - East Melbourne
Recruitment postcode(s) [3] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [4] 0 0
2031 - Randwick
Recruitment postcode(s) [5] 0 0
2298 - Waratah
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Buenos Aires
Country [2] 0 0
Argentina
State/province [2] 0 0
Caba
Country [3] 0 0
Austria
State/province [3] 0 0
Innsbruck
Country [4] 0 0
Austria
State/province [4] 0 0
Linz
Country [5] 0 0
Austria
State/province [5] 0 0
Salzburg
Country [6] 0 0
Austria
State/province [6] 0 0
Wien
Country [7] 0 0
Belgium
State/province [7] 0 0
Charleroi
Country [8] 0 0
Belgium
State/province [8] 0 0
Edegem
Country [9] 0 0
Belgium
State/province [9] 0 0
Leuven
Country [10] 0 0
Brazil
State/province [10] 0 0
Barretos
Country [11] 0 0
Brazil
State/province [11] 0 0
Belo Horizonte
Country [12] 0 0
Brazil
State/province [12] 0 0
Florianópolis
Country [13] 0 0
Brazil
State/province [13] 0 0
Ijui
Country [14] 0 0
Brazil
State/province [14] 0 0
Itajai
Country [15] 0 0
Brazil
State/province [15] 0 0
Porto Alegre
Country [16] 0 0
Brazil
State/province [16] 0 0
Rio de Janeiro
Country [17] 0 0
Brazil
State/province [17] 0 0
Salvador
Country [18] 0 0
Brazil
State/province [18] 0 0
Sao Paulo
Country [19] 0 0
Canada
State/province [19] 0 0
Alberta
Country [20] 0 0
Canada
State/province [20] 0 0
British Columbia
Country [21] 0 0
Canada
State/province [21] 0 0
Ontario
Country [22] 0 0
Canada
State/province [22] 0 0
Quebec
Country [23] 0 0
Canada
State/province [23] 0 0
Regina, Saskatchewan
Country [24] 0 0
China
State/province [24] 0 0
Beijing
Country [25] 0 0
China
State/province [25] 0 0
Changchun
Country [26] 0 0
China
State/province [26] 0 0
Changsha
Country [27] 0 0
China
State/province [27] 0 0
Chengdu
Country [28] 0 0
China
State/province [28] 0 0
Chongqing
Country [29] 0 0
China
State/province [29] 0 0
ChongQing
Country [30] 0 0
China
State/province [30] 0 0
Dalian
Country [31] 0 0
China
State/province [31] 0 0
Fuzhou
Country [32] 0 0
China
State/province [32] 0 0
Guangzhou
Country [33] 0 0
China
State/province [33] 0 0
GuangZhou
Country [34] 0 0
China
State/province [34] 0 0
Haikou
Country [35] 0 0
China
State/province [35] 0 0
Hangzhou
Country [36] 0 0
China
State/province [36] 0 0
Harbin
Country [37] 0 0
China
State/province [37] 0 0
Hefei
Country [38] 0 0
China
State/province [38] 0 0
Hohhot
Country [39] 0 0
China
State/province [39] 0 0
Ji Nan
Country [40] 0 0
China
State/province [40] 0 0
Kunming
Country [41] 0 0
China
State/province [41] 0 0
Linhai
Country [42] 0 0
China
State/province [42] 0 0
Nanchang
Country [43] 0 0
China
State/province [43] 0 0
Nanjing
Country [44] 0 0
China
State/province [44] 0 0
Nanning
Country [45] 0 0
China
State/province [45] 0 0
Nantong
Country [46] 0 0
China
State/province [46] 0 0
Qingdao
Country [47] 0 0
China
State/province [47] 0 0
Shanghai
Country [48] 0 0
China
State/province [48] 0 0
Shenyang
Country [49] 0 0
China
State/province [49] 0 0
Shenzhen
Country [50] 0 0
China
State/province [50] 0 0
Shijiahzhuang
Country [51] 0 0
China
State/province [51] 0 0
Tianjin
Country [52] 0 0
China
State/province [52] 0 0
Urumqi
Country [53] 0 0
China
State/province [53] 0 0
Wuhan
Country [54] 0 0
China
State/province [54] 0 0
Wuxi
Country [55] 0 0
China
State/province [55] 0 0
Xi'an
Country [56] 0 0
China
State/province [56] 0 0
Yancheng
Country [57] 0 0
China
State/province [57] 0 0
Yangzhou
Country [58] 0 0
China
State/province [58] 0 0
Yantai
Country [59] 0 0
China
State/province [59] 0 0
Zhengzhou
Country [60] 0 0
Denmark
State/province [60] 0 0
Vejle
Country [61] 0 0
Ireland
State/province [61] 0 0
Dublin
Country [62] 0 0
Italy
State/province [62] 0 0
Ancona
Country [63] 0 0
Italy
State/province [63] 0 0
Avellino
Country [64] 0 0
Italy
State/province [64] 0 0
Bari
Country [65] 0 0
Italy
State/province [65] 0 0
Bologna
Country [66] 0 0
Italy
State/province [66] 0 0
Brescia
Country [67] 0 0
Italy
State/province [67] 0 0
Cagliari
Country [68] 0 0
Italy
State/province [68] 0 0
Catania
Country [69] 0 0
Italy
State/province [69] 0 0
Firenze
Country [70] 0 0
Italy
State/province [70] 0 0
Genova
Country [71] 0 0
Italy
State/province [71] 0 0
Lecce
Country [72] 0 0
Italy
State/province [72] 0 0
Livorno
Country [73] 0 0
Italy
State/province [73] 0 0
Milano
Country [74] 0 0
Italy
State/province [74] 0 0
Napoli
Country [75] 0 0
Italy
State/province [75] 0 0
Novara
Country [76] 0 0
Italy
State/province [76] 0 0
Palermo
Country [77] 0 0
Italy
State/province [77] 0 0
Parma
Country [78] 0 0
Italy
State/province [78] 0 0
Perugia
Country [79] 0 0
Italy
State/province [79] 0 0
Pisa
Country [80] 0 0
Italy
State/province [80] 0 0
Reggio Emilia
Country [81] 0 0
Italy
State/province [81] 0 0
Roma
Country [82] 0 0
Italy
State/province [82] 0 0
Udine
Country [83] 0 0
Italy
State/province [83] 0 0
Verona
Country [84] 0 0
Korea, Republic of
State/province [84] 0 0
Anyang
Country [85] 0 0
Korea, Republic of
State/province [85] 0 0
Busan
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Cheongju-si
Country [87] 0 0
Korea, Republic of
State/province [87] 0 0
Daegu
Country [88] 0 0
Korea, Republic of
State/province [88] 0 0
Daejeon
Country [89] 0 0
Korea, Republic of
State/province [89] 0 0
Gangneung-si
Country [90] 0 0
Korea, Republic of
State/province [90] 0 0
Goyang-si
Country [91] 0 0
Korea, Republic of
State/province [91] 0 0
Incheon
Country [92] 0 0
Korea, Republic of
State/province [92] 0 0
Jeonju-si
Country [93] 0 0
Korea, Republic of
State/province [93] 0 0
Jeonnam
Country [94] 0 0
Korea, Republic of
State/province [94] 0 0
JinJoo
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Seo-gu
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Seongnam-si
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Seoul
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Suwon-si
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Ulsan
Country [100] 0 0
Saudi Arabia
State/province [100] 0 0
Dammam
Country [101] 0 0
Saudi Arabia
State/province [101] 0 0
Riyadh
Country [102] 0 0
Spain
State/province [102] 0 0
A Coruña
Country [103] 0 0
Spain
State/province [103] 0 0
Alicante
Country [104] 0 0
Spain
State/province [104] 0 0
Badalona
Country [105] 0 0
Spain
State/province [105] 0 0
Barcelona
Country [106] 0 0
Spain
State/province [106] 0 0
Castellón de la Plana
Country [107] 0 0
Spain
State/province [107] 0 0
Jaén
Country [108] 0 0
Spain
State/province [108] 0 0
Las Palmas de Gran Canaria
Country [109] 0 0
Spain
State/province [109] 0 0
León
Country [110] 0 0
Spain
State/province [110] 0 0
Madrid
Country [111] 0 0
Spain
State/province [111] 0 0
Majadahonda
Country [112] 0 0
Spain
State/province [112] 0 0
Oviedo
Country [113] 0 0
Spain
State/province [113] 0 0
Palma de Mallorca
Country [114] 0 0
Spain
State/province [114] 0 0
San Sebastian
Country [115] 0 0
Spain
State/province [115] 0 0
Sevilla
Country [116] 0 0
Spain
State/province [116] 0 0
Valencia
Country [117] 0 0
Spain
State/province [117] 0 0
Zaragoza
Country [118] 0 0
Sweden
State/province [118] 0 0
Orebro
Country [119] 0 0
Sweden
State/province [119] 0 0
Uppsala
Country [120] 0 0
Taiwan
State/province [120] 0 0
Kaohsiung
Country [121] 0 0
Taiwan
State/province [121] 0 0
Taichung
Country [122] 0 0
Taiwan
State/province [122] 0 0
Tainan
Country [123] 0 0
Taiwan
State/province [123] 0 0
Taipei
Country [124] 0 0
Taiwan
State/province [124] 0 0
Taoyuan
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Antrim
Country [126] 0 0
United Kingdom
State/province [126] 0 0
London
Country [127] 0 0
United Kingdom
State/province [127] 0 0
Norwich
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Poole
Country [129] 0 0
United Kingdom
State/province [129] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Parexel
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy.
Trial website
https://clinicaltrials.gov/study/NCT02474355
Trial related presentations / publications
Leighl NB, Kamel-Reid S, Cheema PK, Laskin J, Karsan A, Zhang T, Stockley T, Barnes TA, Tudor RA, Liu G, Owen S, Rothenstein J, Burkes RL, Iqbal M, Spatz A, van Kempen LC, Izevbaye I, Laurence D, Le LW, Tsao MS. Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories. JCO Precis Oncol. 2020 Nov;4:520-533. doi: 10.1200/PO.19.00335.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02474355